Compare ACOG & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACOG | BDSX |
|---|---|---|
| Founded | 2000 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Precision Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.4M | 122.0M |
| IPO Year | N/A | 2020 |
| Metric | ACOG | BDSX |
|---|---|---|
| Price | $5.84 | $14.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $18.00 | ★ $32.50 |
| AVG Volume (30 Days) | 51.4K | ★ 136.3K |
| Earning Date | 03-26-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $88,499,000.00 |
| Revenue This Year | N/A | $25.26 |
| Revenue Next Year | $132.35 | $19.70 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.08 |
| 52 Week Low | $3.75 | $0.25 |
| 52 Week High | $10.88 | $20.21 |
| Indicator | ACOG | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 51.99 | 47.32 |
| Support Level | $5.16 | $6.33 |
| Resistance Level | $6.67 | $20.21 |
| Average True Range (ATR) | 0.32 | 1.69 |
| MACD | -0.01 | -0.56 |
| Stochastic Oscillator | 33.80 | 3.15 |
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.